Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Forced Transdifferentiation

Forced Transdifferentiation

Transdifferentiation, also known as lineage reprogramming, was first discovered by Selman and Kafatos in 1974 in silkmoths. They observed that the moths’ cuticle-producing cells transformed into salt-producing cells. Many such cases of natural transdifferentiation occur in organisms. In humans, pancreatic alpha cells can become beta cells. In newts, the loss of the eye’s lens causes the pigmented epithelial cells to transdifferentiate into the lens cells.
Artificial...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Potential Role of EFR3A in Human Disease States.

Biomolecules·2025

Same author

EFR3A, an Intriguing Gene, and Protein with a Scaffolding Function.

Cells·2025

Same author

Two Variants of the <i>ANK1</i> Gene Associated with Hereditary Spherocytosis.

Biomedicines·2025

Same author

Development of Stable, Maleimide-Functionalized Peptidoliposomes Against SARS-CoV-2.

International journal of molecular sciences·2025

Same author

EFR3A: a new raft domain organizing protein?

Cellular & molecular biology letters·2023

Same author

Novel Variant of the <i>SLC4A1</i> Gene Associated with Hereditary Spherocytosis.

Biomedicines·2023

Same journal

Precision Proteomic Profiling of Systemic Lupus Erythematosus-Correlating Disease Activity and Complement Levels with Clinical Phenotypes.

Biomedicines·2026

Same journal

The Role of Salivary Microbiota in Pancreatic Cancer: From Screening to Tumor Progression and Treatment Response.

Biomedicines·2026

Same journal

Diagnostic Utility of Surface Electromyography for Identifying Muscles Affected by Myofascial Trigger Points: A Scoping Review.

Biomedicines·2026

Same journal

Performance Assessment of a Locally Semi-Automated NGS-Based Workflow for Homologous Recombination Deficiency Testing in High-Grade Serous Ovarian Carcinoma.

Biomedicines·2026

Same journal

Coupling and Uncoupling Pleiotropy Between Hypertension and Type 2 Diabetes Contribute to Exploring Potential Heterogeneity in Cardiovascular Risk in East Asian Population.

Biomedicines·2026

Same journal

Maternal Response to Therapeutic Plasma Exchange in Early Gestation: A Case Series of Thrombotic Microangiopathies and Neurological Disorders.

Biomedicines·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jan 7, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Leukemic Transdifferentiation: From Pathological Plasticity to Dendritic Cell-Based Immunotherapy.

Joanna Dubis¹, Aleksander Czogalla², Kazimierz Kuliczkowski¹

¹Research and Development Centre, Regional Specialist Hospital at Wrocław, Kamieńskiego 73a, 51-124 Wrocław, Poland.

|December 30, 2025

Summary

This summary is machine-generated.

Transdifferentiation transforms mature cells without pluripotency. In leukemia, this process can enhance cancer cell immunogenicity, offering potential for novel immunotherapies targeting leukemia.

Keywords:

dendritic cells immunotherapy leukemia leukemic cell plasticity partial transdifferentiation transdifferentiation

More Related Videos

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Experiment Videos

Last Updated: Jan 7, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Area of Science:

Cell Biology
Immunology
Oncology

Background:

Transdifferentiation is the direct conversion of one differentiated cell to another, bypassing pluripotency.
In leukemia, transdifferentiation impacts tumor survival and treatment resistance.
It also presents opportunities for innovative cancer therapies, particularly by increasing cancer cell immunogenicity.

Purpose of the Study:

To review the molecular mechanisms of transdifferentiation in leukemia.
To highlight the role of dendritic cells in anti-leukemia immunity.
To discuss methods for inducing leukemia cell transformation into antigen-presenting cells for therapeutic applications.

Main Methods:

Review of existing literature on transdifferentiation and leukemia.
Analysis of molecular pathways involved in direct reprogramming.
Examination of in vitro and in vivo techniques for inducing cell transformation.

Main Results:

Transdifferentiation can enhance leukemic cell immunogenicity by promoting dendritic cell-like phenotypes.
Dendritic cells are critical components of both innate and adaptive anti-leukemia immunity.
Specific techniques exist to transform leukemia cells into cancer antigen-presenting cells.

Conclusions:

Harnessing leukemia cell plasticity via transdifferentiation offers a promising avenue for next-generation immunotherapies.
Targeting transdifferentiation could lead to novel anti-leukemia treatments.
Further research into inducing and controlling this process is crucial for therapeutic development.